Sebastian Mirkin

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms
    Sebastian Mirkin
    Pfizer Inc, Collegeville, PA, United States Electronic address
    Maturitas 77:24-31. 2014
  2. doi Tissue-selective estrogen complexes for postmenopausal women
    Sebastian Mirkin
    Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA Electronic address
    Maturitas 76:213-20. 2013
  3. doi Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data
    Sebastian Mirkin
    Pfizer, Inc, 500 Arcola Rd, Room B 4207, Collegeville, PA 19426, USA 1 484 865 4121 1 484 865 8161
    Expert Opin Drug Saf 13:45-56. 2014
  4. doi Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health J V P and Department of Radiology J A H, University of Virginia Health System, Charlottesville, Virginia 22908 Department of Medicine R L, Helen Hayes Hospital, West Haverstraw, New York 10993 Women s Health K P, A A C, S M, Pfizer Inc, Collegeville, Pennsylvania 19426 and Department of Obstetrics and Gynecology D F A, Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23510
    J Clin Endocrinol Metab 99:E189-98. 2014
  5. doi Evolution of the tissue selective estrogen complex (TSEC)
    Barry S Komm
    Pfizer, Inc, Collegeville, Pennsylvania 19426, USA
    J Cell Physiol 228:1423-7. 2013
  6. doi Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women
    Richard J Santen
    Division of Endocrinology and Metabolism R J S, Department of Internal Medicine, University of Virginia, Charlottesville, Virginia 22908 Department of Obstetrics, Gynecology, and Reproductive Sciences R K, University of California San Francisco, San Francisco, California 94143 E Bay Physicians Medical Group R K, Sutter E Bay Medical Foundation, Berkeley, California 94705 Medical Affairs C J A, Women s Health, Pfizer Inc, New York, New York 10017 Medical Affairs B K, S M, Women s Health, Pfizer Inc, Collegeville, Pennsylvania 19426 and Department of Obstetrics, Gynecology, and Reproductive Sciences H S T, Yale School of Medicine, New Haven, Connecticut 06510
    J Clin Endocrinol Metab 99:733-47. 2014
  7. doi Recent advances help understand and improve the safety of menopausal therapies
    Sebastian Mirkin
    From the 1Women s Health, Pfizer Inc, Collegeville, PA 2Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA and 3Department of Obstetrics and Gynecology, Columbia University, New York, NY
    Menopause 22:351-60. 2015
  8. doi Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens
    Andrew G Bushmakin
    From the 1Pfizer Inc, Groton, CT 2Pfizer Ltd, Tadworth, Surrey, UK 3Division of Midlife Health, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA and 4Pfizer Inc, Collegeville, PA
    Menopause 21:815-22. 2014
  9. doi Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling
    Joann V Pinkerton
    From the 1Division of Midlife Health, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 2Pfizer Inc, Groton, CT and 3Pfizer Inc, Collegeville, PA
    Menopause 21:243-51. 2014
  10. doi Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens
    JOHN CHRISTOPHER GALLAGHER
    From the 1Creighton University Medical Center, Omaha, NE and 2Pfizer Inc, Collegeville, PA
    Menopause 20:1126-32. 2013

Detail Information

Publications14

  1. doi Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms
    Sebastian Mirkin
    Pfizer Inc, Collegeville, PA, United States Electronic address
    Maturitas 77:24-31. 2014
    ....
  2. doi Tissue-selective estrogen complexes for postmenopausal women
    Sebastian Mirkin
    Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA Electronic address
    Maturitas 76:213-20. 2013
    ....
  3. doi Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data
    Sebastian Mirkin
    Pfizer, Inc, 500 Arcola Rd, Room B 4207, Collegeville, PA 19426, USA 1 484 865 4121 1 484 865 8161
    Expert Opin Drug Saf 13:45-56. 2014
    ..The safety profile of CEE has been extensively published over the past 20 years...
  4. doi Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health J V P and Department of Radiology J A H, University of Virginia Health System, Charlottesville, Virginia 22908 Department of Medicine R L, Helen Hayes Hospital, West Haverstraw, New York 10993 Women s Health K P, A A C, S M, Pfizer Inc, Collegeville, Pennsylvania 19426 and Department of Obstetrics and Gynecology D F A, Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23510
    J Clin Endocrinol Metab 99:E189-98. 2014
    ..This phase 3 study evaluated the endometrial safety of bazedoxifene (BZA)/conjugated estrogens (CE) and bone mineral density (BMD) effects vs BZA alone, hormone therapy, and placebo (PBO)...
  5. doi Evolution of the tissue selective estrogen complex (TSEC)
    Barry S Komm
    Pfizer, Inc, Collegeville, Pennsylvania 19426, USA
    J Cell Physiol 228:1423-7. 2013
    ..Overall, preclinical studies have shown that estrogens, SERMs, and TSECs each exert distinct and tissue specific molecular and pharmacologic effects...
  6. doi Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women
    Richard J Santen
    Division of Endocrinology and Metabolism R J S, Department of Internal Medicine, University of Virginia, Charlottesville, Virginia 22908 Department of Obstetrics, Gynecology, and Reproductive Sciences R K, University of California San Francisco, San Francisco, California 94143 E Bay Physicians Medical Group R K, Sutter E Bay Medical Foundation, Berkeley, California 94705 Medical Affairs C J A, Women s Health, Pfizer Inc, New York, New York 10017 Medical Affairs B K, S M, Women s Health, Pfizer Inc, Collegeville, Pennsylvania 19426 and Department of Obstetrics, Gynecology, and Reproductive Sciences H S T, Yale School of Medicine, New Haven, Connecticut 06510
    J Clin Endocrinol Metab 99:733-47. 2014
    ..We review the mechanisms of estrogen activity and provide an overview of emerging and available estrogen receptor (ER)-based therapies...
  7. doi Recent advances help understand and improve the safety of menopausal therapies
    Sebastian Mirkin
    From the 1Women s Health, Pfizer Inc, Collegeville, PA 2Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA and 3Department of Obstetrics and Gynecology, Columbia University, New York, NY
    Menopause 22:351-60. 2015
    ..This review provides updates on HT and reviews newer menopausal therapies, focusing on recent safety data...
  8. doi Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens
    Andrew G Bushmakin
    From the 1Pfizer Inc, Groton, CT 2Pfizer Ltd, Tadworth, Surrey, UK 3Division of Midlife Health, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA and 4Pfizer Inc, Collegeville, PA
    Menopause 21:815-22. 2014
    ....
  9. doi Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling
    Joann V Pinkerton
    From the 1Division of Midlife Health, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 2Pfizer Inc, Groton, CT and 3Pfizer Inc, Collegeville, PA
    Menopause 21:243-51. 2014
    ....
  10. doi Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens
    JOHN CHRISTOPHER GALLAGHER
    From the 1Creighton University Medical Center, Omaha, NE and 2Pfizer Inc, Collegeville, PA
    Menopause 20:1126-32. 2013
    ..A post hoc exploratory analysis was conducted to examine correlations between changes in bone density, bone markers, and hot flushes after the treatment of postmenopausal women with bazedoxifene (BZA)/conjugated estrogens (CE)...
  11. doi An overview of current and emerging SERMs
    Barry S Komm
    Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA Electronic address
    J Steroid Biochem Mol Biol 143:207-22. 2014
    ....
  12. doi Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss
    Barry S Komm
    Pfizer Inc, Collegeville, PA, United States Electronic address
    Steroids 90:71-81. 2014
    ..Therefore, CE 0.45 mg/BZA 20 mg is an effective, well-tolerated alternative to EPT for menopausal symptom relief and osteoporosis prevention for postmenopausal women with a uterus...
  13. doi Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
    Sebastian Mirkin
    Pfizer Inc, 500 Arcola Rd, Room B 4207, Collegeville, PA 19426, USA
    Womens Health (Lond Engl) 10:135-46. 2014
    ....